Which valve disease treatment—TAVI or conventional valve replacement—is best for which patient

August 27, 2012

The German Aortic Valve Registry (GARY) was started in July 2010 and is the only registry so far to include both transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacements and repair.(1) The intention is to deliver a complete picture of current and future practice of treating aortic valve disease and to deliver reliable data on the short and long-term outcome of different treatment strategies. This specifically includes data about quality of life before and after treatment besides numerous medical variables.

Participation in the registry is on a voluntary basis, with 92 German centres (from a possible 99) actively taking part at present. The registry is planned to include patients up to 2015 and to gather a one, three and five-year follow up. It is expected that a total of about 80,000 patients will eventually be enrolled.

By July 2012 more than 26,000 patients were included, of whom 23% were TAVI patients. Current data include 15,252 patients treated in 2011 from 53 centres (when the registry was still in its run-in phase).

First results, presented today at ESC Congress 2012 by Professor Friedrich-Wilhelm Mohr, Clinic Director of the Leipzig Heart Centre, Germany, show that participating centres generally adhered to current guidelines for patient selection; 85% of all TAVI patients were over 75 years and had a higher calculated peri-operative risk of . The mean age of patients who received isolated elective and urgent conventional was 68.3 (±11.3) years, with a logistic EuroSCORE (log. ES) of 8.8% (±9.7%). TAVI patients were on average significantly older (transfemoral 81.0 [±6.1] years, transapical 80.3 [±6.1] years) and with a higher operative risk.

The reported in-hospital mortality for elective patients was 2.1% for , 5.1% for the transfemoral TAVI and 7.7% for the transapical approach. These numbers confirm the good results of recent studies and reflect the growing experience in treatment and perioperative management of aortic . The high procedural success of more than 97% and the low rate of valve-related reinterventions (less than 0.5%) are also indicative of the latest improvements.

Stratification of the patients into risk groups revealed a particular benefit for people with high (log. ES >20%) and very high (log. ES >30%) risk when treated transfemorally, with mortality rates of 4.7% and 7.7%, respectively.

Consistent with earlier observations, the overall number of cerebrovascular events during hospital stay was low in the conventionally treated group (2.2%) and somewhat higher for TAVI patients (transfemoral 3.7%, transapical 3.5%). The rate of vascular complications was reported as 11.9% for the transfemoral, 2.5% for the transapical and 1.0% for the conventional group. However, the number of patients who needed more than two units of packed red blood cells was 29.4% in conventional surgery and 25.4% with the transapical, but only 11.5% with the transfemoral approach.

The number of postoperatively new pacemaker was 23.7% in the transfemoral group - significantly higher than in the transapical (9.9%) and in the conventional surgical groups (4.6%). Here, significant differences between the two predominantly transfemorally implanted valve types were noted (29.4% Corevalve, 12.1% Edwards Sapien). The amount of residual aortic regurgitation was also reported to be different with the Corevalve (grade 0 29.6%, grade I or II 70.0%, more than grade II 0.4%) and the Edwards Sapien® prosthesis (grade 0 53.8%, grade I or II 45.7%, more than grade II 0.4%).

Commenting on the results, Professor Mohr said: "From these first data it can be concluded that the patients in the participating German centres were treated according to the guidelines, which led to low in-hospital mortality in all groups as compared to former surveys. Patients in high risk groups benefit at least as much from TAVI procedures as from conventional surgery, particularly when performed transfemorally.

"Post-procedural rates of cerebrovascular events, vascular complications, renal failure and blood transfusions have decreased but need further attention. The high number of in the register will allow for thorough risk factor analysis for these complications. Additional long-term follow-up is to evaluate the high number of pacemaker implants as well as residual aortic regurgitation in the TAVI group. The German registry was especially designed to make an important contribution to the ongoing discussion on these subjects. With the help of subgroup analyses and stratification for risk factors, we also expect to detect which treatment is best for which patient."

GARY was inaugurated by the German Society of Cardiology and the German Society for Thoracic and Cardiovascular Surgery because of the remarkable growing numbers of TAVI over the past few years. It is supported by the German Heart Foundation and receives unrestricted grants from the heart valve manufacturing industry.

Explore further: Gender differences in clinical presentation and outcome of transcatheter aortic valve implantation

Related Stories

Gender differences in clinical presentation and outcome of transcatheter aortic valve implantation

August 29, 2011
Severe aortic stenosis (AS) is increasing in frequency as the population ages. For a subset of patients in whom surgical conventional aortic valve replacement is excluded due to severe co-morbidities, an alternative to surgical ...

Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis

April 10, 2012
German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis—a special form of aortic stenosis that is difficult to treat. Results published ...

Results of the STACCATO Trial reported at TCT 2011

November 10, 2011
Researchers leading a clinical trial said that transapical transcatheter aortic valve implantation (a-TAVI) may be inferior to surgical aortic valve replacement (SAVR) in operable elderly patients. However results were only ...

Hemodynamic results after Transcatheter Aortic Valve Implantation (TAVI)

August 30, 2011
Since 2007 Transcatheter Aortic Valve Implantation (TAVI) has become an alternative treatment for elderly patients with severe aortic stenosis at high risk for surgical aortic valve replacement. At present, durability and ...

Recommended for you

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017
Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal ...

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

Proteome of the human heart mapped for the first time

November 15, 2017
A healthy heart beats about two billion times during a lifetime, thanks to the interplay of more than 10,000 proteins. Researchers from the Max Planck Institute of Biochemistry (MPIB) and the German Heart Centre at the Technical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.